In a prospective clinical trial comparing EPO to supportive care in patients with lower‐risk MDS, the response rate was better in the EPO arm (36.0% vs. 9.6%) but the crossover design of the study prevented assessment of long‐term survival 14. Here, EPO is linked to myelodysplastic syndrome.